At the end of the year, we all like to navel gaze, and editors are no different. It's a good time to reflect on what we write about, the importance of…
The move positions Loxo to wrap up the filing for the Bayer-partnered TRK inhibitor early next year.
Alnylam, which put its hemophilia program on hold in September, has gotten the all-clear from the FDA to resume trials.
Officials want firms to team up to test multiple candidates in single trials, thereby cutting the number of patients who receive placebos.
Ultragenyx Pharmaceuticals chalked up another win for its rare bone disease drug, burosumab, keeping it on track for a U.S. regulatory filing.
Australia’s Prescient Therapeutics is getting its lead cancer program back on track, with two trials subject to FDA clinical hold cleared to resume.
After tying with Milan in a third round of voting, Amsterdam will be the new home of the European Medicines Agency.
Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.
The action marks the end for an oral adenosine A2a receptor antagonist Acorda paid $363 million in cash for last year.
Controversial plans to allow the Pentagon to approve drugs and medical devices intended for use by soldiers have been set aside in the latest version of the…